Cognigenics has developed a new RNA-based therapy, COG-201, showing promise in improving memory and reducing anxiety in animals by targeting the serotonin 5-HT2A receptor. The therapy, administered intranasally, could revolutionize treatment for cognitive impairments and mood disorders. RNA-Based Therapy in Neuroscience Scientists at Cognigenics have made a significant advance in the field of neuroscience and […]
Source link
